Global Anti-IL-23 p19 Monoclonal Antibodies Market Strategic Research Report

Scope of the Report

The global Anti-IL-23 p19 Monoclonal Antibodies market size is predicted to grow from US$ 23,576 million in 2025 to US$ 46,859 million in 2032; it is expected to grow at a CAGR of 8.8% from 2026 to 2032.

Anti-IL-23 p19 monoclonal antibodies are recombinant therapeutic biologics designed to selectively bind the p19 subunit of interleukin 23 and treat immune-mediated inflammatory diseases. The product scope mainly covers humanized or fully human IgG monoclonal antibody injections, including prefilled syringes, autoinjectors, subcutaneous formulations and intravenous induction formulations used in selected indications. Core manufacturing processes include antibody discovery and optimization, mammalian cell expression, cell culture, protein A purification, viral inactivation, ultrafiltration and concentration, aseptic filling, cold-chain release testing and biologics quality control. Key specifications include target-binding affinity, p19 selectivity, serum half-life, dosing interval, immunogenicity, formulation stability, purity, aggregate level, potency and batch-to-batch consistency. The main therapeutic function is to inhibit IL-23-mediated activation of the Th17 inflammatory pathway and reduce downstream cytokine activity, thereby improving chronic inflammatory diseases such as moderate to severe plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. The industry is positioned within specialty biologics and autoimmune therapeutics, with demand driven by long-term treatment, expanded indications, improved dosing convenience and substitution from older immunology therapies. In 2025, mature commercialized anti-IL-23 p19 monoclonal antibody products generally achieved gross margins of about 80% to 90%.

Anti-IL-23 p19 monoclonal antibodies represent one of the most commercially established segments within specialty immunology biologics. The market is not characterized by a large number of manufacturers, but by a small group of approved therapies that have built strong positions through clear target selectivity, durable efficacy, convenient dosing and continuous indication expansion. The upstream chain includes cell line development, culture media, single-use bioreactors, purification resins, sterile filling materials and cold-chain systems. The midstream consists of antibody discovery, clinical development, regulatory registration, large-scale biologics manufacturing and quality release. The downstream market is concentrated in dermatology, rheumatology and gastroenterology, where chronic disease management and long treatment duration support resilient demand. Competition is highly concentrated, but the basis of competition is changing. Initial adoption was largely driven by plaque psoriasis, while future growth is increasingly linked to inflammatory bowel disease, psoriatic arthritis and broader immune-mediated conditions. New product launches and indication expansion remain the main commercial catalysts, but differentiation must be supported by sustained efficacy, safety, dosing convenience and real-world outcomes. Licensing, co-development and regional commercialization agreements are expected to remain active, particularly around late-stage pipelines and next-generation antibody formats. These transactions can improve development efficiency and accelerate geographic expansion, but they also make revenue attribution and market sizing more complex. The policy environment is broadly supportive of innovative biologics, especially where therapies address chronic inflammatory diseases with high unmet needs. At the same time, payer pressure, health technology assessment, price negotiation, biosimilar risk and patent-cycle dynamics will gradually moderate long-term growth. The industry remains a growth market, but it is moving from a rapid expansion phase toward a more mature phase driven by product differentiation and lifecycle management. Products with longer half-life, fewer injections, broader indication coverage and reliable manufacturing quality are likely to gain share, while late entrants with limited clinical or pricing advantages may face increasing commercialization pressure.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Anti-IL-23 p19 Monoclonal Antibodies market?

What factors are driving Anti-IL-23 p19 Monoclonal Antibodies market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Anti-IL-23 p19 Monoclonal Antibodies market opportunities vary by end market size?

How does Anti-IL-23 p19 Monoclonal Antibodies break out by Indication, by Application?

This report presents a comprehensive overview of the global Anti-IL-23 p19 Monoclonal Antibodies market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Molecule Type

• Humanized IgG Monoclonal Antibodies
• Fully Human IgG Monoclonal Antibodies
• Fc-engineered or Long-acting Antibodies
• Others

Segment by Indication

• Plaque Psoriasis
• Psoriatic Arthritis
• Crohn's Disease
• Ulcerative Colitis
• Others

Segment by Route of Administration

• Subcutaneous Injection
• Intravenous Induction plus Subcutaneous Maintenance
• Intravenous Injection
• Others

Segment by Application

• Hospitals
• Specialist Clinics
• Infusion Centers
• Specialty Pharmacies
• Retail and DTP Pharmacies
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Anti-IL-23 p19 Monoclonal Antibodies market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hospitals, Specialist Clinics, Infusion Centers evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact